Press Release

Sequantrix signs agreement with Chugai to use the AI-driven DiseaseDecoder for drug development

Aachen, Germany, 28th April, 2025. Sequantrix (SQX) announced today that it signed an agreement with Chugai Pharmaceutical Co., Ltd. for the use of its AI-driven DiseaseDecoder technology for drug development projects at Chugai.

The DiseaseDecoder has been developed by SQX as a proprietary computational framework for the identification and evaluation of targets using AI and high quality multimodal single-cell and spatial OMICS data. DiseaseDecoder utilizes an extensive suite of AI-based algorithms custom-built for handling large volumes of high-dimensional data to provide a deep biological understanding of the pathophysiology at single-cell resolution.

The computational framework allows SQX to discover novel targets, predict effects of target engagement by modelling in silico perturbation and address project-specific questions such as the identification of possible patient inclusion criteria for clinical development.

SQX has originally developed the DiseaseDecoder platform for applications in fibrosis and is now expanding its use to allow in-depth analysis of single-cell and spatial OMICS data for a broad range of diseases.

"We are excited to welcome Chugai as our first partner for the DiseaseDecoder platform. This agreement marks the start of our ambitious strategy, offering drug co-development opportunities as well as providing access to our DiseaseDecoder and Patient-on-Chip organoid technology to accelerate preclinical drug development." said SQX Co-Founder and CEO Dr. Michael Rheinnecker.

About Sequantrix

Sequantrix was created by leading pioneers in fibrosis research, clinical care and computational science to address the large, unmet medical need for anti-fibrotic therapies. The spin-out from the University Hospital Aachen leverages one of the world's largest human multimodal, single-cell datasets in the field of fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to the clinical proof of concept.

Contact

info@sequantrix.bio